Yasin Keshvargar

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…

Davis Polk advised the representative of the initial purchasers in connection with the debut Rule 144A/Regulation S offering by LD Holdings Group LLC of $500 million aggregate principal…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127…

Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Energizer Holdings, Inc. of $800 million aggregate principal…

 Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross proceeds of $204 million. ADC Therapeutics is listed on the New York…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,200,000 shares of common stock of…

Davis Polk advised Spirit Airlines, Inc. in connection with a Rule 144A/Regulation S offering of $850 million aggregate principal amount of 8% senior notes due 2025 by Spirit IP Cayman Ltd…

Davis Polk advised the lead placement agent in connection with I-Mab’s $418 million private placement of 29,133,502 ordinary shares and warrants to subscribe for 5,341,267 ordinary shares…

Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of 5,500,000 American Depositary Shares of BioNTech SE. In addition,…